new glp-1 retatrutide for weight loss: Study shows 30% body weight loss Unapproved weight loss drug retatrutide
Description
Radiolabeled exendin-based PET/CT imaging using 68 Ga or 111 In enable real-time mapping of receptor density
2013;110(22):9066-9071 doi:10.1073/pnas.1219451110 (Animal) Depommier C, Everard A, Druart C, et al
Nearly 25% of the population in western countries have NAFLD and up to 6.5% fulfill the criteria of NASH ( NAFLD is considered the hepatic manifestation of metabolic syndrome ( No pharmacological therapies are approved for the treatment of NAFLD and lifestyle changes focusing on caloric restriction and weight loss constitute the general treatment recommendations
Physiol Behav (2008) 94(5):6704
